Aardvark Therapeutics (AARD) Operating Leases (2024 - 2025)

Aardvark Therapeutics (AARD) reported Operating Leases of $116000.0 for Q3 2025, down 49.12% sequentially from $228000.0 in Q2 2025.

Aardvark Therapeutics (AARD) Operating Leases (2024 - 2025) Analysis & Trends

Aardvark Therapeutics (AARD) has 2 years of Operating Leases data on file, last reported at $116000.0 in Q3 2025.

For the quarter ending Q3 2025, Operating Leases changed N/A year-over-year to $116000.0; the trailing twelve-month figure through Sep 2025 stood at $116000.0 (changed N/A YoY), and the FY2024 full-year result was $441000.0, changed N/A from the prior year.
Operating Leases retreated to $116000.0 in Q3 2025, from $228000.0 in the prior quarter.
In the past five years, Operating Leases ranged from a high of $441000.0 in Q4 2024 to a low of $116000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Aardvark Therapeutics	139.40 Mn	19.44 Mn	-

Download Data